Search research articles
Contact Us
Filters
Showing results (171-180 of 265) with videos related to
Page
of 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Annals of Surgical Oncology
|
September 19, 2013
Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype
Lee J McGhan, Ann E McCullough, Cheryl A Protheroe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Cancer
|
October 16, 2012
Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial
Matthew R Callstrom, Damian E Dupuy, Stephen B Solomon, et al.
Nature Communications
|
January 10, 2017
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Tongzheng Liu, Jia Yu, Min Deng, et al.
Breast Cancer Research and Treatment
|
May 20, 2023
Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast
Utsav Joshi, Pravash Budhathoki, Suman Gaire, et al.
Therapeutic Advances in Medical Oncology
|
February 9, 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
Shani Paluch-Shimon, Patrick Neven, Jens Huober, et al.
JCI Insight
|
July 24, 2020
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
Junmei Cairns, James N Ingle, Tanda M Dudenkov, et al.
Nature Communications
|
January 27, 2022
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Nicola Cosgrove, Damir Varešlija, Stephen Keelan, et al.
Pharmacogenetics and Genomics
|
July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
James N Ingle, Krishna R Kalari, Poulami Barman, et al.
Page
of 27
Search research articles
Search
Showing results (171-180 of 265) with videos related to
Sort By:
Page
of 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Annals of Surgical Oncology
|
September 19, 2013
Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype
Lee J McGhan, Ann E McCullough, Cheryl A Protheroe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Cancer
|
October 16, 2012
Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial
Matthew R Callstrom, Damian E Dupuy, Stephen B Solomon, et al.
Nature Communications
|
January 10, 2017
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Tongzheng Liu, Jia Yu, Min Deng, et al.
Breast Cancer Research and Treatment
|
May 20, 2023
Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast
Utsav Joshi, Pravash Budhathoki, Suman Gaire, et al.
Therapeutic Advances in Medical Oncology
|
February 9, 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
Shani Paluch-Shimon, Patrick Neven, Jens Huober, et al.
JCI Insight
|
July 24, 2020
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
Junmei Cairns, James N Ingle, Tanda M Dudenkov, et al.
Nature Communications
|
January 27, 2022
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Nicola Cosgrove, Damir Varešlija, Stephen Keelan, et al.
Pharmacogenetics and Genomics
|
July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
James N Ingle, Krishna R Kalari, Poulami Barman, et al.
Page
of 27